T1	Participants 95 125	head-and-neck cancer patients.
T2	Participants 245 298	patients with head-and-neck squamous cell carcinomas.
T3	Participants 357 428	65 patients with head-and-neck squamous cell carcinoma nodal metastasis
T4	Participants 581 646	Fifty-four patients had sufficient tumor cells for comet analysis
